Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C19 | P33261 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 4/20 | 0.36 |
| ▸ | HTT | P42858 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.34 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.34 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15544175 | 1.00 | CYP2C19 (0.37) | CYP2C19ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL15545353 | 0.86 | ALDH1A1 (0.39) | CYP2C19ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL16680148 | 0.84 | CYP2C19 (0.39) | CYP2C19ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL17467169 | 0.81 | CYP2C19 (0.42) | CYP2C19ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL17467166 | 0.81 | CYP2C19 (0.42) | CYP2C19ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL15081220 | 0.75 | CYP2C19 (0.42) | CYP2C19ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL3318266 | 0.75 | CTSV (0.48) | CYP2C19ALDH1A1KMT2AMEN1MAPT | |
| SCHEMBL15545435 | 0.72 | KMT2A (0.44) | CYP2C19ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL15545438 | 0.72 | KMT2A (0.44) | CYP2C19ALDH1A1KMT2AMEN1CYP1A2 | |
| SCHEMBL16680219 | 0.72 | CYP1A2 (0.52) | CYP2C19KMT2AMEN1CYP1A2GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | NXERA PHARMA UK LIMITED (GB) | 2016-07-28 | — | — | US | disclosed |
| EP-2870144-A1 | OREXIN RECEPTOR ANTAGONISTS | Heptares Therapeutics Limited (GB) | 2015-05-13 | — | — | EP | disclosed |
| WO-2014006402-A1 | OREXIN RECEPTOR ANTAGONISTS | HEPTARES THERAPEUTICS LIMITED (GB) | 2014-01-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160213678-A1 | OREXIN RECEPTOR ANTAGONISTS | HCRTR2, HCRTR1, NPY4R | CYP2C19 2065/4885ALDH1A1 3165/4885KMT2A 1060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.